Endonovo Therapeutics (ENDV) Notes Payables (2016 - 2023)
Endonovo Therapeutics has reported Notes Payables over the past 12 years, most recently at $7.1 million for Q3 2023.
- Quarterly results put Notes Payables at $7.1 million for Q3 2023, up 268.85% from a year ago — trailing twelve months through Sep 2023 was $7.1 million (up 268.85% YoY), and the annual figure for FY2022 was $7.2 million, down 1.28%.
- Notes Payables for Q3 2023 was $7.1 million at Endonovo Therapeutics, roughly flat from $7.1 million in the prior quarter.
- Over the last five years, Notes Payables for ENDV hit a ceiling of $7.3 million in Q4 2021 and a floor of $152000.0 in Q2 2020.
- Median Notes Payables over the past 5 years was $1.9 million (2022), compared with a mean of $3.4 million.
- Biggest five-year swings in Notes Payables: crashed 94.99% in 2019 and later soared 1672.43% in 2020.
- Endonovo Therapeutics' Notes Payables stood at $6.9 million in 2019, then decreased by 0.58% to $6.8 million in 2020, then grew by 6.17% to $7.3 million in 2021, then decreased by 1.28% to $7.2 million in 2022, then fell by 1.1% to $7.1 million in 2023.
- The last three reported values for Notes Payables were $7.1 million (Q3 2023), $7.1 million (Q2 2023), and $6.9 million (Q1 2023) per Business Quant data.